- Investing Ideas
- Global Pharmaceuticals & Biotech Pure Equity Growth
Global Pharmaceuticals & Biotech Pure Equity Growth
Results
43
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
43 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: US$126.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
SKBH.F
US$50.16
7D
0%
1Y
n/a
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$126.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$528.50
7D
9.7%
1Y
30.9%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$126.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$528.50
7D
9.7%
1Y
30.9%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$126.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$528.50
7D
7.5%
1Y
26.3%
Praxis Precision Medicines
Market Cap: US$10.2b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$370.68
7D
19.5%
1Y
664.9%
Krystal Biotech
Market Cap: R$10.1b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
K1YS34
R$44.80
7D
0%
1Y
n/a
Camurus
Market Cap: SEK 37.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 622.00
7D
3.4%
1Y
-2.1%
Camurus
Market Cap: SEK 37.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
0RD1
SEK 621.00
7D
3.0%
1Y
-2.3%
Camurus
Market Cap: SEK 37.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMXS
SEK 625.00
7D
0%
1Y
-2.0%
Camurus
Market Cap: €37.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
7CA
€57.10
7D
3.0%
1Y
0.2%
Camurus
Market Cap: US$36.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMR.F
US$58.51
7D
0%
1Y
-17.6%
BioArctic
Market Cap: US$28.4b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BRCT.F
US$31.78
7D
0%
1Y
39.0%
BioArctic
Market Cap: SEK 28.3b
Develops biological drugs for patients with central nervous system disorders in Sweden.
0RV2
SEK 320.07
7D
1.5%
1Y
43.9%
BioArctic
Market Cap: SEK 28.3b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 319.00
7D
1.2%
1Y
45.0%
BioArctic
Market Cap: SEK 28.3b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOABS
SEK 328.40
7D
0%
1Y
45.8%
BioArctic
Market Cap: €28.3b
Develops biological drugs for patients with central nervous system disorders in Sweden.
B9A
€28.80
7D
0.1%
1Y
50.2%
Zymeworks
Market Cap: US$1.7b
A biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
ZYME
US$24.32
7D
6.7%
1Y
86.8%
Zymeworks
Market Cap: €1.7b
A biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
ZA8
€20.68
7D
11.0%
1Y
102.7%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 225.20
7D
1.2%
1Y
-26.4%
Bonesupport Holding
Market Cap: US$14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BOEU.F
US$22.94
7D
12.0%
1Y
-28.3%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
0RQO
SEK 226.40
7D
0.1%
1Y
-25.0%
Bonesupport Holding
Market Cap: €14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
2B4
€20.66
7D
-1.7%
1Y
-24.6%
Bonesupport Holding
Market Cap: SEK 14.6b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEXS
SEK 219.70
7D
0%
1Y
-35.2%
CARsgen Therapeutics Holdings
Market Cap: HK$9.0b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.13
7D
13.8%
1Y
n/a
CARsgen Therapeutics Holdings
Market Cap: HK$9.0b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.13
7D
13.8%
1Y
n/a
CARsgen Therapeutics Holdings
Market Cap: US$9.0b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
CRTH.F
US$1.89
7D
-1.6%
1Y
n/a
CARsgen Therapeutics Holdings
Market Cap: HK$9.0b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$15.82
7D
12.2%
1Y
-24.9%
Kuros Biosciences
Market Cap: CHF 914.8m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 23.06
7D
0.4%
1Y
-12.8%
Kuros Biosciences
Market Cap: CHF 914.8m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
0RHR
CHF 23.04
7D
-0.7%
1Y
-11.8%
Kuros Biosciences
Market Cap: €914.8m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
YTSN
€23.16
7D
-4.1%
1Y
-15.4%
Kuros Biosciences
Market Cap: CHF 914.8m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURNz
CHF 22.94
7D
-0.8%
1Y
-13.1%
Kuros Biosciences
Market Cap: US$888.6m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
CSBT.F
US$29.62
7D
15.8%
1Y
-17.4%
BioPorto
Market Cap: €574.3m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
2P4
€0.14
7D
-5.5%
1Y
-13.4%
BioPorto
Market Cap: DKK 574.3m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
BIOPOR
DKK 1.16
7D
-1.3%
1Y
-10.8%
BioPorto
Market Cap: DKK 559.5m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
0JJM
DKK 1.12
7D
-12.8%
1Y
n/a
BioPorto
Market Cap: US$524.8m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
THOX.F
US$0.15
7D
0%
1Y
n/a